A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects

Trial Profile

A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs AT 527 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Proof of concept
  • Sponsors Atea Pharmaceuticals
  • Most Recent Events

    • 31 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 14 Apr 2018 Results presented at The International Liver Congress 2018
    • 12 Apr 2018 Results presented in the Atea pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top